{
    "Trade/Device Name(s)": [
        "COBAS INTEGRA Bilirubin Direct Gen.2",
        "Bilirubin Direct Gen.2"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "k123965",
    "Predicate Device Reference 510(k) Number(s)": [
        "k063543"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG"
    ],
    "Summary Letter Date": "February 28, 2013",
    "Summary Letter Received Date": "December 26, 2012",
    "Submission Date": "December 21, 2012",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Direct Bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Li-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Gel separation tube"
    ],
    "Instrument(s)/Platform(s)": [
        "COBAS INTEGRA 800"
    ],
    "Method(s)/Technology(ies)": [
        "Diazo colorimetric method",
        "Photometric measurement"
    ],
    "Methodologies": [
        "Colorimetric quantitation"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for COBAS INTEGRA Bilirubin Direct Gen.2 reagent, a colorimetric assay for direct bilirubin quantitation on COBAS INTEGRA systems",
    "Indications for Use Summary": "In vitro test for quantitative determination of direct bilirubin in human serum and plasma on COBAS INTEGRA systems, aiding in the diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders.",
    "fda_folder": "Clinical Chemistry"
}